Results 121 to 130 of about 5,882 (203)

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics. [PDF]

Signal Transduct Target Ther
Loy CA, Gu Y, Kim SC, Mohagheghi MV, Trask NB, Suarez-Pizarro M, Wagar LE, Benavente CA, Trader DJ.   +8 more
europepmc   +1 more source

Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. [PDF]

Arthritis Res Ther
Ghannam K, My LN, Behrendt C, Brunner-Weinzierl M, Lux A, Bertrand J, Wille A, Gläß M, Heinemann-Dammann S, Borucki K, Feist E.   +10 more
europepmc   +1 more source

Sex-specific remodeling of proteasome complexes in lymph nodes of aged BTBR mice. [PDF]

Front Aging
Monittola F, Bruschi M, Masini S, Losito DP, Magnani M, Rossi L, Fraternale A, Crinelli R.   +7 more
europepmc   +1 more source

Type I and II Interferon Signalling Characterizes the Transcriptional Landscape of Sweet Syndrome. [PDF]

Exp Dermatol
Calabrese L, Moltrasio C, Romagnuolo M, Stadler PC, Fiocco Z, Neulinger-Muñoz M, Aoki R, D'Onghia M, Rubegni P, Kerl K, Satoh TK, Marzano AV, French LE.   +12 more
europepmc   +1 more source

PA200 modulates immunoproteasome structure and activity. [PDF]

Nat Commun
Živković D, Bosc-Rosati A, Dafun AS, Mourtada F, Grygier P, Yazgili AS, Jansma M, Rawski M, Czarna A, Bohn S, Zak KM, Santos Dias Mourão A, Reiling N, Zemke L, Guo K, Behr J, Burlet-Schiltz O, Popowicz GM, Marcoux J, Meiners S, Bousquet MP.   +20 more
europepmc   +1 more source

Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines. [PDF]

Int J Mol Sci
Sattarifard H, Oyeyode M, Prajapati D, Duaqui A, Kaur G, Muker I, Luo W, Lakowski TM, Davie JR.   +8 more
europepmc   +1 more source

Pharmacokinetics, Target Engagement of an Immunoproteasome Subunit Low-Molecular-Mass Polypeptide‑2 (LMP2) Inhibitor AR-01, and Its Anti-Alzheimer's Effects in Rodents. [PDF]

ACS Pharmacol Transl Sci
Thapa Magar TB, Kim M, Kim Y, Choi EY, Choi YK, Kim DE, Kim KB, Park JE.   +7 more
europepmc   +1 more source

Dominant-negative PSMB10 disrupts immunoproteasome assembly and leads to transient T lymphopenia. [PDF]

J Hum Immun
Ghosh S, Wang Y, Schultheiss C, Borkhardt A, Dafun AS, Knipp L, Marwitz S, Ehl S, Soulard C, Haddad E, Dey D, Evans G, Golwala ZM, Bennstein SB, Laws HJ, Rohlfs M, Magg T, Binder M, Kreins AY, Bousquet MP, Marcoux J, Klein C, Conn GL, Meiners S, Hauck F.   +24 more
europepmc   +1 more source

Monoallelic PSMB8 variants cause PRAAS with immunodeficiency through impaired immunoproteasome assembly. [PDF]

Am J Hum Genet
Wijngaard R, van der Made CI, Kalkan Uçar S, Ramakrishnan G, Wang M, Brand J, Rosenfeld JA, Vogel TP, Nicholas SK, Weisz-Hubshman M, Undiagnosed Diseases Network, van Karnebeek CDM, Allenspach EJ, Gardiner TE, Perera Kimmantudawage S, Stark Z, Armstrong RK, Campbell J, Volpi S, Drago E, Gattorno M, Grossi A, Ceccherini I, Cabrera-Orefice A, Siebels B, Mair T, Schlüter H, Smeets RL, van Beek R, Goebel I, Küchler K, Gersting SW, Hoischen A, Vissers LELM, Wevers RA, Meyer-Schwesinger C, Wortmann SB, Oud MM, Guerrero-Castillo S.   +38 more
europepmc   +1 more source

Messing with Signal 1: How Perturbed MHC Class I Antigen Presentation Contributes to Cancer. [PDF]

Cells
Lawand M, Al Rayess S, Jaber R, van Endert P.   +3 more
europepmc   +1 more source